Previous 10 | Next 10 |
Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance PR Newswire CINCINNATI , Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial r...
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q4 earnings results on Friday, November 12th, before market open. The consensus EPS Estimate is $0.20 (+5.3% Y/Y) and the consensus Revenue Estimate is $68.4M (+6.6% Y/Y). Over the last 2 years, VIVO has beaten EPS estimates 88% of th...
AZN, BKKT, BKSY, BPTH, CAAS, CASI, OTCQX:CCHWF, CGEN, OTCQX:DTEGF, EMAN, GP, OTCPK:HNHAF, HYZN, ITRM, MIR, MOTS, NGD, NXTD, PX, SOHO, SPB, STRR, OTCPK:TOSBF, VERO, OTCPK:VITFF, VIVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earn...
Meridian Bioscience (NASDAQ:VIVO) announces that their Revogene SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. FDA. Shares jump more than 7% premarket. The Revogene SARS-CoV-2 assay is a molecular diagnostic test for the qualitative detection of...
Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay PR Newswire CINCINNATI , Nov. 10, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life sc...
Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples PR Newswire CINCINNATI , Oct. 27, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing...
Miller/Howard Investments is an employee-owned, research-driven firm managing portfolios for a range of investors, from high-net-worth individuals to large institutions. We now hold Texas Instruments, NetApp, Broadcom, and Cisco, all of which have strong growth prospects, yet attracti...
Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021 PR Newswire CINCINNATI , Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic ...
Meridian Launches New Air-Dryable™ qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples PR Newswire CINCINNATI , Oct. 7, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solut...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with this event. For further details see: Meridian Bioscience (VIVO) Presents 23rd Annual Global Investment Virtual Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...